Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 40%Moderate 2 · 40%High 0 · 0%

Adverse events during treatment period · people with acute ischemic stroke

Calcium antagonists showed no clear difference in adverse events during treatment period compared with placebo (moderate certainty).

1 finding from 1 review

Calcium antagonists for acute ischemic stroke 2019 · Cochrane Headline outcomes only
RR 1.18 [0.81, 1.74]
13 studies · 5095 participants
Moderate

Adverse events during treatment period · people with acute ischemic stroke

Other calcium antagonists showed no clear difference in adverse events during treatment period compared with placebo (low certainty).

1 finding from 1 review

Calcium antagonists for acute ischemic stroke 2019 · Cochrane Headline outcomes only
RR 1.19 [0.52, 2.72]
1 study · 160 participants
Low

Adverse events during treatment period · people with acute ischemic stroke

Nimodipine showed no clear difference in adverse events during treatment period compared with placebo (moderate certainty).

1 finding from 1 review

Calcium antagonists for acute ischemic stroke 2019 · Cochrane Headline outcomes only
RR 0.93 [0.74, 1.16]
11 studies · 4604 participants
Moderate

Adverse events during treatment period · people with acute ischemic stroke

Flunarizine may leads to higher adverse events during treatment period compared with placebo (low certainty).

1 finding from 1 review

Calcium antagonists for acute ischemic stroke 2019 · Cochrane Headline outcomes only
RR 3.16 [1.91, 5.21]
1 study · 331 participants
Low

Adverse events during treatment period · people with acute ischemic stroke

The review found no eligible studies for this question.

1 finding from 1 review

Calcium antagonists for acute ischemic stroke 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found